Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective
更正：在有症状的慢性阻塞性肺疾病患者中，乌美溴铵/维兰特罗 62.5/25 微克与噻托溴铵/奥达特罗 5/5 微克的成本效益分析：西班牙国家医疗保健系统视角
期刊:Respiratory Research
影响因子:5
doi:10.1186/s12931-019-0985-2
Driessen, M T; Whalen, J; Buguth, B Seewoodharry; Vallejo-Aparicio, L A; Naya, I P; Asukai, Y; Alcázar-Navarrete, B; Miravitlles, M; García-Río, F; Risebrough, N A
